Phase 3 Clinical Trials With Primary Completion Dates in April 2020

This is a list of Phase 3 trials with primary completion dates in April 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
CBDY Target Group Inc. 2020-04-01 Phase 3 NCT03180307 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
CHHL China Holdings, Inc. 2020-04-01 Phase 3 NCT02971345 Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
DCTH Delcath Systems, Inc. 2020-04-01 Phase 3 NCT02678572 Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
IMMU Immunomedics, Inc. 2020-04-01 Phase 3 NCT02574455 ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer
INO Inovio Pharmaceuticals, Inc. 2020-04-01 Phase 3 NCT03185013 REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NERV Minerva Neurosciences, Inc. 2020-04-01 Phase 3 NCT03397134 Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
OPHLY Ono Pharmaceutical Co., Ltd. 2020-04-01 Phase 3 NCT03117049 Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)